|
|
DSpace at RU >
University Library >
Academic bibliography >
|
| Title: | Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy. |
| Author(s): | Karakiewicz, P.I. Jeldres, C. Suardi, N. Hutterer, G.C. Perrotte, P. Capitanio, U. Ficarra, V. Cindolo, L. Taille, A de la Tostain, J. Mulders, P.F.A. (106661302) Salomon, L. Zigeuner, R. Schips, L. Chautard, D. Valeri, A. Lechevallier, E. Descots, J.L. Lang, H. Mejean, A. Verhoest, G. Patard, J.J. |
| Publication year: | 2008 |
| Document type: | Article / Letter to editor |
| Journal: | Canadian Urological Association Journal |
| ISSN: | 1911-6470 |
| Volume: | vol. 2 |
| Issue: | iss. 6 |
| Start page: | p. 610 |
| End page: | p. 617 |
| Abstract: | OBJECTIVE: Based on combined data for 4880 patients, 2 previous studies reported that advanced age is a predictor of increased renal cell carcinoma-specific mortality (RCC-SM). We explored the effect of age in cubic spline analyses to identify the age groups with the most elevated risk for renal cell carcinoma (RCC). METHODS: Our study included 3595 patients from 14 European centres who had partial or radical nephrectomies. We used the Kaplan-Meier method to compile life tables, and we performed Cox regression analyses to assess RCC-SM. Covariates included age at diagnosis, sex, TNM (tumour, node, metastasis) stage, tumour size, Fuhrman grade, symptom classification and histological subtype. RESULTS: Age ranged from 10 to 89 (mean 63, median 67) years. The median duration of follow-up was 2.9 years. The median survival for the cohort was 13.4 years. Stage distribution was as follows: 1915 patients (53.3%) had stage I disease, 388 (10.8%) had stage II, 895 (24.9%) had stage III and 397 (11.0%) had stage IV disease. In multivariate analyses, we coded age at diagnosis as a cubic spline, and it achieved independent predictor status (p < 0.001). The risk of RCC-SM was lowest among patients younger than 50 years. We observed an increase in RCC-SM until the age of 50, at which point the level of risk reached a plateau. We observed a second increase among patients aged 75-89 years. We found similar patterns when we stratified patients according to the 2002 American Joint Committee on Cancer (AJCC) stages. CONCLUSION: The effect of age shows prognostic significance and indicates that follow-up and possibly secondary treatments might need to be adjusted according to the age of the patient. |
| Subject: | UMCN 1.2: Molecular diagnosis, prognosis and monitoring |
| Organization: | Urology |
| Appears in Collections: | Academic bibliography
|
|
Please use this identifier to cite or link to this item:
http://hdl.handle.net/2066/69586
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|
|